Usmani, S., Bories, P., Gasparetto, C., Dingli, D., Lonial, S., Siegel, D., … Stadtmauer, E. (2025). Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma. In Blood (Vol. 146, pp. 250–250). American Society of Hematology. https://doi.org/10.1182/blood-2025-250

Usmani, Saad, Pierre Bories, Cristina Gasparetto, David Dingli, Sagar Lonial, David Siegel, Andrew Yee, et al. “Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma.” In Blood, 146:250–250. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-250.

Usmani S, Bories P, Gasparetto C, Dingli D, Lonial S, Siegel D, et al. Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma. In: Blood. American Society of Hematology; 2025. p. 250–250.

Usmani, Saad, et al. “Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 250–250. Crossref, doi:10.1182/blood-2025-250.

Usmani S, Bories P, Gasparetto C, Dingli D, Lonial S, Siegel D, Yee A, Varga C, Trudel S, Rosiñol Dachs L, Rodriguez-Otero P, Manier S, Berdeja J, Afrough A, Baker W, Hasheminasab SA, Thakurta A, Sridharan V, Flynt E, Barnett M, Versmee L, Mateos M-V, Touzeau C, Chung A, Roy V, Stadtmauer E. Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma. Blood. American Society of Hematology; 2025. p. 250–250.